Metabasis Type 2 Diabetes Candidate Successful In Phase IIa Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After last year's disappointing Phase IIb results from a type 2 diabetes candidate, Metabasis Therapeutics is hoping for better luck with MB07803. The company said April 28 that the second-generation gluconeogenesis inhibitor met its primary efficacy endpoint in a Phase IIa study
You may also be interested in...
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.
Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago